Epigenomics is a leading journal in the realms of Cancer Research and Genetics, published by Future Medicine Ltd in the United Kingdom. With an ISSN of 1750-1911 and an E-ISSN of 1750-192X, the journal has been an integral part of the scientific community since its inception in 2009, and is set to converge its impactful research publications through 2024. The journal occupies a significant position in its category quartiles as evidenced by its ranking—Q3 in Cancer Research and Q2 in Genetics as of 2023. With Scopus rankings of #138/347 in Genetics and #113/230 in Cancer Research, it demonstrates scholarly excellence and is recognized for its contributions to understanding the role of epigenetic modifications in health and disease. While Epigenomics operates under traditional subscription models, it remains a vital resource for researchers, professionals, and students eager to explore the complex interplay between genes and the epigenome. The journal's innovative approach to epigenetics and its impact on cancer research makes it essential reading for those at the forefront of biomedical research.

DNA AND CELL BIOLOGY, published by Mary Ann Liebert, Inc, is a distinguished journal in the realms of cell biology, genetics, and molecular biology, holding a notable position in its Q3 and Q2 quartile rankings across multiple academic categories as of 2023. With an ISSN of 1044-5498 and an E-ISSN of 1557-7430, this journal has been a pivotal platform for the dissemination of cutting-edge research since its inception in 1990, extending its coverage through 2024. Situated in the United States, the journal offers high-quality peer-reviewed articles, exploring significant advancements in biological sciences while fostering interdisciplinary collaborations within the research community. Though it currently does not offer open access, subscribed institutions and individual readers benefit from its rich repository of knowledge. The journal's rigorous standards and impactful content make it an essential resource for researchers, professionals, and students alike, aiming to stay at the forefront of discoveries influencing DNA and cellular dynamics.

BIOCHEMICAL GENETICS, published by Springer/Plenum Publishers, is a prominent journal in the fields of biochemistry, genetics, and molecular biology, with a substantial impact on the scientific community since its inception in 1967. The journal holds a significant position within various academic quartiles, ranking Q2 in Ecology, Evolution, Behavior and Systematics, and Q3 in Biochemistry, Genetics, and Medicine (miscellaneous), among others, demonstrating its diverse and interdisciplinary reach. With an ISSN of 0006-2928 and an E-ISSN of 1573-4927, it is recognized for contributing critical research insights and methodologies that drive the fields of biochemical genetics forward. Although it is not an Open Access journal, it provides vital access options and resources for researchers globally, facilitating the dissemination of knowledge across institutions. Positioned within the competitive landscape of Scopus rankings, it maintains respectable standings across its focused areas, making it an invaluable resource for researchers, professionals, and students seeking to deepen their understanding of genetic mechanisms and biochemical processes.

GENOMICS is a prestigious journal published by Academic Press Inc Elsevier Science, dedicated to advancing the field of genetic research and molecular biology. With an impressive impact factor, this journal is recognized for its rigorous peer-review process and high-quality publications that cover a wide range of topics within the genomics discipline. Operating from the United States, GENOMICS has established itself as a vital resource for researchers, professionals, and students alike, standing at Q2 in the Genetics category according to the latest rankings. With a rich history dating back to 1987 and convergence extending to 2024, the journal highlights cutting-edge discoveries and methodologies, ensuring that its readership remains at the forefront of genetic advancements. Although currently not an open-access journal, articles published within its pages are often accessible through various academic platforms, enhancing worldwide reach and dissemination. For those engaged in the fields of biochemistry, genetics, and molecular biology, GENOMICS serves as an indispensable platform for impactful research and collaborative initiatives.

FUNCTIONAL & INTEGRATIVE GENOMICS, published by Springer Heidelberg, is a leading journal in the fields of genetics and molecular biology. Established in 2000, it serves as a pivotal platform for advancing our understanding of genomic functionality and integration, making significant contributions to both basic and applied research in genetics. With a robust impact factor and a ranking in the Q3 quartile for Genetics and Q2 for Medicine (Miscellaneous), the journal aims to publish innovative research that explores the relationships between genomic data and biological functions, appealing to a diverse audience of researchers and professionals. Although it operates under a subscription model, the journal's extensive archives remain a valuable resource for academics seeking to stay abreast of the latest findings and methodologies in genomics. As the field evolves, FUNCTIONAL & INTEGRATIVE GENOMICS remains committed to fostering scholarly dialogue and the dissemination of groundbreaking studies that influence future research trajectories.

International Journal of Molecular Medicine is a prestigious publication dedicated to advancing the field of molecular medicine through innovative research and scholarly dialogue. Published by Spandidos Publications Ltd in Greece, this journal has successfully provided a platform for academics and professionals alike since its inception in 1998. With an impressive 2023 Q1 ranking in Medicine (Miscellaneous) and a Q2 ranking in Genetics, the journal maintains a vital role in disseminating high-quality research, underscored by its strong performance in the Scopus rankings, particularly in the realm of genetics where it ranks 28 out of 347. Researchers will benefit from its comprehensive scope, which encompasses a wide range of topics within molecular biology, genetics, and their clinical applications. Although the journal does not operate under an open access model, it remains influential, providing critical insights that contribute significantly to the understanding and development of molecular therapeutic strategies and innovations.

Epigenetics, published by Taylor & Francis Inc, is a leading journal in the fields of Cancer Research, Medicine (miscellaneous), and Molecular Biology. With an ISSN of 1559-2294 and an E-ISSN of 1559-2308, this journal has been paving the way for groundbreaking research since its inception in 2006, and it continues to play a crucial role in advancing our understanding of epigenetic mechanisms and their implications in health and disease. The journal is highly regarded, ranking in the Q1 category for Medicine and Q2 for both Cancer Research and Molecular Biology according to the 2023 category quartiles. Researchers and professionals in the field will find invaluable insights and innovative studies within its pages, making it an essential resource for those engaged in cutting-edge research. Although the journal is not open access, it encourages a comprehensive understanding through high-quality peer-reviewed content. With its creative exploration of the epigenetic landscape, Epigenetics serves as a vital platform for the sharing of knowledge that could lead to breakthroughs in treatments and therapies.

CELL BIOLOGY AND TOXICOLOGY, published by SPRINGER, stands as a vital journal within the realms of cell biology and toxicology, boasting an impressive 2023 Q1 ranking in its fields, alongside robust Scopus rankings placing it in the top 11th percentile for Toxicology and the 22nd for Health, Toxicology and Mutagenesis. With an ISSN of 0742-2091 and an E-ISSN of 1573-6822, the journal has been a cornerstone of scientific discourse since its inception in 1984, and will continue to converge innovative research until 2024. The journal focuses on the interplay between cellular mechanisms and toxicological implications, making it an essential resource for researchers, healthcare professionals, and students keen on advancing their understanding of these critical areas. Although it does not offer open access, its high impact and prestigious standing ensure that its publications reach a wide audience dedicated to significant advancements in the life sciences.

GENES & DEVELOPMENT, published by COLD SPRING HARBOR LAB PRESS, stands as a premier journal in the fields of Developmental Biology and Genetics, boasting a remarkable impact factor that reflects its prestigious position in the academic community—ranking Q1 in both disciplines as of 2023. Since its inception in 1987, this journal has been at the forefront of disseminating cutting-edge research, effectively bridging the gap between laboratory breakthroughs and their applications in health and disease. Researchers and professionals rely on GENES & DEVELOPMENT for its rigorous peer-review process and its commitment to promoting innovative studies that unravel the complexities of gene functions and developmental processes. With Scopus rankings placing it in the top percentile among its peers, this journal serves as a vital resource for students and established scientists alike, aspiring to expand their knowledge and contribute to the ever-evolving landscape of genetic and developmental research.

GENE, an esteemed journal published by Elsevier, serves as a vital resource for researchers and professionals in the fields of genetics and medicine. With an ISSN of 0378-1119 and an E-ISSN of 1879-0038, this scholarly journal has been at the forefront of genetic research since its inception in 1976 and is set to continue until 2025. Situated in the Netherlands, GENE is recognized for its significant contributions, reflected in its Q2 ranking in both Genetics and Miscellaneous Medicine categories for 2023. This positioning within the Scopus rankings demonstrates its impact and relevance in a competitive field, where it holds the rank of #129 out of 347 in Genetics, placing it within the 62nd percentile. Although it does not offer open access options, GENE provides invaluable insight into contemporary genetic research, thereby fostering academic discussions and advancements. Researchers, professionals, and students alike will find GENE an essential platform for disseminating knowledge and exploring innovative developments in genetics and associated sciences.